お知らせ :東京証券取引所JASDAQスタンダード市場への新規上場に関するお知らせ

株式会社グローバルインフォメーション
市場調査レポート
商品コード
948547

多発性硬化症治療の世界市場:タイプ(免疫抑制剤と免疫調節剤)、投与経路(経口、注射、および静脈内)別の機会分析および業界予測(2019年~2026年)

Multiple Sclerosis Therapies Market by Type (Immunosuppressants and Immunomodulators) and Route of Administration (Oral, Injectable, and Intravenous): Global Opportunity Analysis and Industry Forecast, 2019-2026

出版日: | 発行: Allied Market Research | ページ情報: 英文 151 Pages | 納期: 2-3営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=104.53円
多発性硬化症治療の世界市場:タイプ(免疫抑制剤と免疫調節剤)、投与経路(経口、注射、および静脈内)別の機会分析および業界予測(2019年~2026年)
出版日: 2020年05月01日
発行: Allied Market Research
ページ情報: 英文 151 Pages
納期: 2-3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の多発性硬化症治療市場は、2018年に2,299万米ドルとなりました。同市場は、2019年から2026年にかけて2.5%のCAGRで成長する見通しで、2026年には2,800万米ドルに達すると予測されいます。治療の選択肢としての疾患修飾薬の導入は、世界のMS治療薬市場の成長を牽引する重要な要因となっています。さらに、経口薬への選好の変化によっても同市場の成長は推進されています。ただし、この病気の病因が不明であり、医学研究者が病気の主要原因をターゲットにした薬剤を開発することが困難であることは同市場の課題となっています。

当レポートは世界の多発性硬化症治療市場について調査しており、市場機会や影響、成長および阻害要因、タイプ・投与経路・地域別の市場分析、競合情勢、主要企業のプロファイル等の情報を提供しています。

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 市場概要

  • 市場の定義と範囲
  • 主な調査結果
    • 主な投資銘柄
    • 成功戦略
  • 市場力学
    • 成長要因
      • パイプライン薬の数の増加
      • 患者数の急増
      • 患者支援プログラム(PAP)の急増
    • 抑制要因
      • 病因不明
    • 市場機会
      • 疾患修飾薬のイントロダクション
      • 適応外医薬品の使用

第4章 市場分析:タイプ別

  • 概観
    • 市場規模と予測
  • 免疫抑制剤
  • 免疫調節剤

第5章 市場分析:投与経路別

  • 概観
    • 市場規模と予測
  • 経口
  • 注射剤
  • 静脈内

第6章 市場分析:地域別

  • 概観
    • 市場規模と予測
  • 北米
    • 主な市場動向と機会
    • 市場分析:国ごと
      • 米国
      • カナダ
      • メキシコ
  • 欧州
    • 主な市場動向と機会
    • 市場分析:国ごと
      • 英国
      • ドイツ
      • フランス
      • イタリア
      • スペイン
      • その他
  • アジア太平洋地域
    • 主な市場動向と機会
    • 市場分析:国ごと
      • 日本
      • 中国
      • オーストラリア
      • インド
      • その他
  • ラテンアメリカ・中東・アフリカ
    • 主な市場動向と機会
    • 市場分析:国ごと
      • ブラジル
      • 南アフリカ
      • サウジアラビア
      • その他

第7章 企業プロファイル

  • ABBVIE INC.
  • BAYER AG.
  • BIOGEN
  • BRISTOL-MYERS SQUIBB COMPANY
  • F. HOFFMANN-LA ROCHE LTD.
  • MERCK KGAA
  • NOVARTIS AG.
  • PFIZER INC.
  • SANOFI
  • TEVA PHARMACEUTICAL INDUSTRIES LTD.
図表

LIST OF TABLES

  • TABLE 01.GLOBAL MS THERAPIES MARKET, BY TYPE, 2018-2026 ($MILLION)
  • TABLE 02.IMMUNOSUPPRESSANTS MS THERAPIES MARKET, BY REGION, 2018-2026 ($MILLION)
  • TABLE 03.IMMUNOMODULATORS MS THERAPIES MARKET, BY REGION, 2018-2026 ($MILLION)
  • TABLE 04.GLOBAL MS THERAPIES MARKET, BY ROUTE OF ADMINISTRATION, 2018-2026 ($MILLION)
  • TABLE 05.MS THERAPIES MARKET FOR ORAL, BY REGION, 2018-2026 ($MILLION)
  • TABLE 06.INJECTABLE MS THERAPIES MARKET, BY REGION, 2018-2026 ($MILLION)
  • TABLE 07.MS THERAPIES MARKET FOR INTRAVENOUS, BY REGION, 2018-2026 ($MILLION)
  • TABLE 08.MS THERAPIES MARKET, BY REGION, 2018-2026 ($MILLION)
  • TABLE 09.NORTH AMERICA MS THERAPIES MARKET REVENUE, BY COUNTRY 2019-2026 ($MILLION)
  • TABLE 10.U.S. MS THERAPIES MARKET REVENUE, BY TYPE 2018-2026 ($MILLION)
  • TABLE 11.U.S. MS THERAPIES MARKET REVENUE, BY ROUTE OF ADMINISTRATION, 2018-2026 ($MILLION)
  • TABLE 12.CANADA MS THERAPIES MARKET REVENUE, BY TYPE 2018-2026 ($MILLION)
  • TABLE 13.CANADA MS THERAPIES MARKET REVENUE, BY ROUTE OF ADMINISTRATION, 2018-2026 ($MILLION)
  • TABLE 14.MEXICO MS THERAPIES MARKET REVENUE, BY TYPE 2018-2026 ($MILLION)
  • TABLE 15.MEXICO MS THERAPIES MARKET REVENUE, BY ROUTE OF ADMINISTRATION, 2018-2026 ($MILLION)
  • TABLE 16.EUROPE MS THERAPIES MARKET REVENUE, BY COUNTRY 2018-2026 ($MILLION)
  • TABLE 17.UK MS THERAPIES MARKET REVENUE, BY TYPE 2018-2026 ($MILLION)
  • TABLE 18.UK MS THERAPIES MARKET REVENUE, BY ROUTE OF ADMINISTRATION, 2018-2026 ($MILLION)
  • TABLE 19.GERMANY MS THERAPIES MARKET REVENUE, BY TYPE 2018-2026 ($MILLION)
  • TABLE 20.GERMANY MS THERAPIES MARKET REVENUE, BY ROUTE OF ADMINISTRATION, 2018-2026 ($MILLION)
  • TABLE 21.FRANCE MS THERAPIES MARKET REVENUE, BY TYPE 2018-2026 ($MILLION)
  • TABLE 22.FRANCE MS THERAPIES MARKET REVENUE, BY ROUTE OF ADMINISTRATION, 2018-2026 ($MILLION)
  • TABLE 23.ITALY MS THERAPIES MARKET REVENUE, BY TYPE 2018-2026 ($MILLION)
  • TABLE 24.ITALY MS THERAPIES MARKET REVENUE, BY ROUTE OF ADMINISTRATION, 2018-2026 ($MILLION)
  • TABLE 25.SPAIN MS THERAPIES MARKET REVENUE, BY TYPE 2018-2026 ($MILLION)
  • TABLE 26.SPAIN MS THERAPIES MARKET REVENUE, BY ROUTE OF ADMINISTRATION, 2018-2026 ($MILLION)
  • TABLE 27.REST OF EUROPE MS THERAPIES MARKET REVENUE, BY TYPE 2018-2026 ($MILLION)
  • TABLE 28.REST OF EUROPE MS THERAPIES MARKET REVENUE, BY ROUTE OF ADMINISTRATION, 2018-2026 ($MILLION)
  • TABLE 29.ASIA-PACIFIC MS THERAPIES MARKET REVENUE, BY COUNTRY 2018-2026 ($MILLION)
  • TABLE 30.JAPAN MS THERAPIES MARKET REVENUE, BY TYPE 2018-2026 ($MILLION)
  • TABLE 31.JAPAN MS THERAPIES MARKET REVENUE, BY ROUTE OF ADMINISTRATION, 2018-2026 ($MILLION)
  • TABLE 32.CHINA MS THERAPIES MARKET REVENUE, BY TYPE 2018-2026 ($MILLION)
  • TABLE 33.CHINA MS THERAPIES MARKET REVENUE, BY ROUTE OF ADMINISTRATION, 2018-2026 ($MILLION)
  • TABLE 34.AUSTRALIA MS THERAPIES MARKET REVENUE, BY TYPE 2018-2026 ($MILLION)
  • TABLE 35.AUSTRALIA MS THERAPIES MARKET REVENUE, BY ROUTE OF ADMINISTRATION, 2018-2026 ($MILLION)
  • TABLE 36.INDIA MS THERAPIES MARKET REVENUE, BY TYPE 2018-2026 ($MILLION)
  • TABLE 37.INDIA MS THERAPIES MARKET REVENUE, BY ROUTE OF ADMINISTRATION, 2018-2026 ($MILLION)
  • TABLE 38.REST OF ASIA-PACIFIC MS THERAPIES MARKET REVENUE, BY TYPE 2018-2026 ($MILLION)
  • TABLE 39.REST OF ASIA-PACIFIC MS THERAPIES MARKET REVENUE, BY ROUTE OF ADMINISTRATION, 2018-2026 ($MILLION)
  • TABLE 40.LAMEA MS THERAPIES MARKET REVENUE, BY COUNTRY 2018-2026 ($MILLION)
  • TABLE 41.BRAZIL MS THERAPIES MARKET REVENUE, BY TYPE 2018-2026 ($MILLION)
  • TABLE 42.BRAZIL MS THERAPIES MARKET REVENUE, BY ROUTE OF ADMINISTRATION, 2018-2026 ($MILLION)
  • TABLE 43.SOUTH AFRICA MS THERAPIES MARKET REVENUE, BY TYPE 2018-2026 ($MILLION)
  • TABLE 44.SOUTH AFRICA MS THERAPIES MARKET REVENUE, BY ROUTE OF ADMINISTRATION, 2018-2026 ($MILLION)
  • TABLE 45.SAUDI ARABIA MS THERAPIES MARKET REVENUE, BY TYPE 2018-2026 ($MILLION)
  • TABLE 46.SAUDI ARABIA MS THERAPIES MARKET REVENUE, BY ROUTE OF ADMINISTRATION, 2018-2026 ($MILLION)
  • TABLE 47.REST OF LAMEA MS THERAPIES MARKET REVENUE, BY TYPE 2018-2026 ($MILLION)
  • TABLE 48.REST OF LAMEA MS THERAPIES MARKET REVENUE, BY ROUTE OF ADMINISTRATION, 2018-2026 ($MILLION)
  • TABLE 49.ABBVIE: COMPANY SNAPSHOT
  • TABLE 50.ABBVIE: OPERATING BUSINESS SEGMENTS
  • TABLE 51.ABBVIE: PRODUCT PORTFOLIO
  • TABLE 52.BAYER.: COMPANY SNAPSHOT
  • TABLE 53.BAYER.: OPERATING SEGMENTS
  • TABLE 54.BAYER.: PRODUCT PORTFOLIO
  • TABLE 55.BIOGEN: COMPANY SNAPSHOT
  • TABLE 56.AMGEN: PRODUCT PORTFOLIO
  • TABLE 57.BMS: COMPANY SNAPSHOT
  • TABLE 58.BMS: OPERATING SEGMENTS
  • TABLE 59.BMS: PRODUCT PORTFOLIO
  • TABLE 60.ROCHE: COMPANY SNAPSHOT
  • TABLE 61.ROCHE: OPERATING SEGMENTS
  • TABLE 62.MERCK: COMPANY SNAPSHOT
  • TABLE 63.MERCK: OPERATING BUSINESS SEGMENTS
  • TABLE 64.MERCK: PRODUCT PORTFOLIO
  • TABLE 65.NOVARTIS: COMPANY SNAPSHOT
  • TABLE 66.NOVARTIS: OPERATING SEGMENTS
  • TABLE 67.NOVARTIS: PRODUCT PORTFOLIO
  • TABLE 68.PFIZER: COMPANY SNAPSHOT
  • TABLE 69.PFIZER: OPERATING SEGMENTS
  • TABLE 70.PFIZER: PRODUCT PORTFOLIO
  • TABLE 71.SANOFI: COMPANY SNAPSHOT
  • TABLE 72.SANOFI: OPERATING SEGMENTS
  • TABLE 73.SANOFI: PRODUCT PORTFOLIO
  • TABLE 74.TEVA: COMPANY SNAPSHOT
  • TABLE 75.TEVA: PRODUCT PORTFOLIO

LIST OF FIGURES

  • FIGURE 01.GLOBAL MS THERAPIES DEVICES MARKET SEGMENTATION
  • FIGURE 02.TOP INVESTMENT POCKETS
  • FIGURE 03.TOP WINNING STRATEGIES, BY YEAR, 2016-2019*
  • FIGURE 04.TOP WINNING STRATEGIES, BY COMPANY, 2016-2019*
  • FIGURE 05.TOP IMPACTING FACTORS
  • FIGURE 06.DRUGS IN DEVELOPMENT, 2019
  • FIGURE 07.COMPARATIVE ANALYSIS OF IMMUNOSUPPRESSANTS MS THERAPIES MARKET BY COUNTRY, 2018 & 2026 (%)
  • FIGURE 08.COMPARATIVE ANALYSIS OF IMMUNOMODULATORS MS THERAPIES MARKET, BY COUNTRY, 2018 & 2026 (%)
  • FIGURE 09.ORAL MS THERAPIES MARKET, BY COUNTRY, 2018 & 2026 (%)
  • FIGURE 10.MS THERAPIES MARKET FOR INJECTABLE, BY COUNTRY, 2018 & 2026 (%)
  • FIGURE 11.MS THERAPIES MARKET FOR INTRAVENOUS, BY COUNTRY, 2018 & 2026 (%)
  • FIGURE 12.ABBVIE: NET SALES, 2016-2018 ($MILLION)
  • FIGURE 13.ABBVIE: REVENUE SALESBY SEGMENT,2018 (%)
  • FIGURE 14.ABBVIE: REVENUE SHARE BY REGION, 2018(%)
  • FIGURE 15.BAYER: NET SALES, 2016-2018 ($MILLION)
  • FIGURE 16.BAYER: REVENUE SHARE BY SEGMENT, 2018 (%)
  • FIGURE 17.BAYER: REVENUE SHARE BY REGION, 2018(%)
  • FIGURE 18.BIOGEN: NET SALES, 2016-2018 ($MILLION)
  • FIGURE 19.BMS: NET SALES, 2016-2018 ($MILLION)
  • FIGURE 20.BMS: REVENUE SHARE BY REGION, 2018(%)
  • FIGURE 21.ROCHE: NET SALES, 2016-2018 ($MILLION)
  • FIGURE 22.ROCHE: REVENUE SHARE BY SEGMENT, 2018 (%)
  • FIGURE 23.ROCHE: REVENUE SHARE BY GEOGRAPHY, 2018 (%)
  • FIGURE 24.MERCK: NET SALES, 2016-2018 ($MILLION)
  • FIGURE 25.MERCK: REVENUE SHARE BY SEGMENT, 2018 (%)
  • FIGURE 26.MERCK: REVENUE SHARE BY REGION, 2018(%)
  • FIGURE 27.NOVARTIS: NET SALES, 2016-2018 ($MILLION)
  • FIGURE 28.NOVARTIS: REVENUE SHARE BY SEGMENT, 2018 (%)
  • FIGURE 29.NOVARTIS: REVENUE SHARE BY REGION, 2018 (%)
  • FIGURE 30.PFIZER: NET SALES, 2016-2018 ($MILLION)
  • FIGURE 31.PFIZER: REVENUE SHARE BY SEGMENT, 2018 (%)
  • FIGURE 32.PFIZER: REVENUE SHARE BY REGION, 2018(%)
  • FIGURE 33.SANOFI: NET SALES, 2016-2018 ($MILLION)
  • FIGURE 34.SANOFI: REVENUE SHARE BY SEGMENT, 2018 (%)
  • FIGURE 35.SANOFI: REVENUE SHARE BY REGION, 2018(%)
  • FIGURE 36.TEVA: NET SALES, 2016-2018 ($MILLION)
  • FIGURE 37.TEVA: REVENUE SHARE BY REGION, 2018(%)
目次
Product Code: A01119

The global multiple sclerosis therapies market was valued at $22.99 million in 2018, and is projected to reach $28.00 million by 2026, registering a CAGR of 2.5% from 2019 to 2026. Multiple sclerosis is a chronic, inflammatory medical condition, which results in demyelination, axonal transection, and neurodegeneration of the nerve cells of the brain and spinal cord. The immune system of the body targets the neurons within the central nervous system and damages the myelin sheath. It is a potentially debilitating disease, causing disruption in communication and coordination functions of the body. The symptoms of multiple sclerosis differ widely, subject to the extent of damage and the number of neurons affected. Some of the symptoms observed are fatigue, numbness, spasticity, bladder dysfunction, cognitive changes, emotional changes, and depression. An individual suffering from severe MS experiences speech and movement problems. Multiple sclerosis can be broadly classified into four types, RRMS, SPMS, PPMS, and PRMS.

One of the major challenges in the global MS therapies market is the unknown etiology of the disease. Thus, it is difficult for medical researchers to develop drugs that target the key source of the disease. However, the introduction of disease-modifying drugs as a treatment option is a key factor that drives the growth of the global MS therapies market. In addition, the growth of the global MS therapies market is driven by shift in preference toward oral drugs. For example, drugs such as Copaxone (Glatiramer Acetate) by Teva Pharmaceuticals and Tysabri (Natalizumab) by Biogen Idec are increasingly used in the treatment of multiple sclerosis.

Moreover, increase in number of pipeline drugs is anticipated to offer remunerative opportunities for market expansion during the forecast period. Daclizumab, RG1594 (Ocrelizumab), and Lemtrada (Alemtuzumab) are the novel late stage pipeline products likely to enter the market during the forecast period. The launch of new pipeline products is expected to change the present market scenario, which is dependent on injectable formulations (such as Avonex, Betaseron/Betaferon, Rebif, Copaxone, and Tysabri). These drugs need to be injected frequently, and their dose frequency ranges from daily to weekly administration. Some of the new drugs are oral formulations (Aubagio and BG-12) while others are injectable formulations (Daclizumab, Ocrelizumab, and Alemtuzumab), and all require dosing either once a month or once every six months. Therefore, these drugs are expected to be well-tolerated and improve patient compliance. In addition, the price of these products is expected to be lower than the price of the current products. Some of these products have shown superior efficacy (BG-12 and Lamtrada) in clinical trials compared with the currently approved products (Copaxone and Rebif).

The global MS therapies market is segmented into type, route of administration, and region. On the basis of type, the market is classified into immunosuppressants and immunomodulators. Depending on route of administration, the market is divided into oral, injectable, and intravenous. Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA. The major revenue contributor in the MS therapies market is North America, and is expected to continue this trend during the forecast period owing to rise in the U.S. FDA approvals for medications used in the treatment of MS, followed by Europe and Asia-Pacific. However, lack of medications to cure multiple sclerosis hampers the growth of the global market. This is attributed to the fact that there are no standard established treatment procedures for multiple sclerosis. Therefore, increase in R&D activities to develop medications for the treatment of multiple sclerosis is expected to drive the market growth during the forecast period.

The major companies profiled in the global MS therapies market include Abbvie Inc., Bayer AG, Biogen, Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd., Merck KGaA, Novartis AG, Pfizer Inc., Sanofi, and Teva Pharmaceutical Industries Ltd.

KEY BENEFITS FOR STAKEHOLDERS

This report provides a detailed quantitative analysis of the current global multiple sclerosis therapies market trends and future estimations from 2019-2026, which assists to identify the prevailing market opportunities.

An in-depth analysis of various regions is anticipated to provide a detailed understanding of the current trends to enable stakeholders to formulate region-specific plans.

A comprehensive analysis of the factors that drive and restrain the growth of the global multiple sclerosis therapies market is provided.

An extensive analysis of various regions provides insights that allow companies to strategically plan their business moves.

KEY MARKET SEGMENTS

BY TYPE

  • Immunosuppressants
  • Immunomodulators

BY ROUTE OF ADMINISTRATION

  • Oral
  • Injectable
  • Intravenous

BY REGION

  • North America
  • U.S.
  • Canada
  • Mexico
  • Europe
  • Germany
  • France
  • Spain
  • Italy
  • UK
  • Rest of Europe
  • Asia-Pacific
  • Japan
  • India
  • China
  • Australia
  • Rest of Asia-Pacific
  • LAMEA
  • Brazil
  • Saudi Arabia
  • South Africa
  • Rest of LAMEA
  • KEY MARKET PLAYERS
  • Abbvie Inc.
  • Bayer AG
  • Biogen
  • Bristol-Myers Squibb Company
  • F. Hoffmann-La Roche Ltd.
  • Merck KGaA
  • Novartis AG
  • Pfizer Inc.
  • Sanofi
  • Teva Pharmaceutical Industries Ltd.

TABLE OF CONTENTS

CHAPTER 1:INTRODUCTION

  • 1.1.Report description
  • 1.2.Key benefits for stakeholders
  • 1.3.Key market segments
  • 1.4.Research methodology
    • 1.4.1.Secondary research
    • 1.4.2.Primary research
    • 1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

  • 2.1.Key findings of the study
  • 2.2.CXO perspective

CHAPTER 3:MARKET OVERVIEW

  • 3.1.Market definition and scope
  • 3.2.Key findings
      • 3.2.1.1.Top investment pockets
    • 3.2.2.Top winning strategies
  • 3.3.Market dynamics
    • 3.3.1.Drivers
      • 3.3.1.1.Increase in number of pipeline drugs
      • 3.3.1.2.Upsurge in patient population
      • 3.3.1.3.Surge in number of patient assistance programs (PAPs )
    • 3.3.2.Restraint
      • 3.3.2.1.Unspecified etiology of the disease
    • 3.3.3.Opportunities
      • 3.3.3.1.Introduction of disease-modifying drugs
      • 3.3.3.2.Use of off-label drugs

CHAPTER 4:MS THERAPIES MARKET, BY TYPE

  • 4.1.Overview
    • 4.1.1.Market size and forecast
  • 4.2.Immunosuppressants
    • 4.2.1.Key market trends, growth factors, and opportunities
    • 4.2.2.Market size and forecast, by region
    • 4.2.3.Market analysis, by country
  • 4.3.Immunomodulators
    • 4.3.1.Key market trends, growth factors, and opportunities
    • 4.3.2.Market size and forecast, by region
    • 4.3.3.Market analysis, by country

CHAPTER 5:MS THERAPIES MARKET, BY ROUTE OF ADMINISTRATION

  • 5.1.Overview
    • 5.1.1.Market size and forecast
  • 5.2.Oral
    • 5.2.1.Market size and forecast, by region
    • 5.2.2.Market analysis, by country
  • 5.3.Injectable
    • 5.3.1.Market size and forecast, by region
    • 5.3.2.Market analysis, by country
  • 5.4.Intravenous
    • 5.4.1.Market size and forecast, by region
    • 5.4.2.Market analysis, by country

CHAPTER 6:MS THERAPIES MARKET, BY REGION

  • 6.1.Overview
    • 6.1.1.Market size and forecast
  • 6.2.North America
    • 6.2.1.Key market trends and opportunities
    • 6.2.2.Market analysis by country
      • 6.2.2.1.U.S.
      • 6.2.2.1.1.U.S. market size and forecast, by type
      • 6.2.2.1.2.U.S. market size and forecast, by route of administration
      • 6.2.2.2.Canada
      • 6.2.2.2.1.Canada market size and forecast, by type
      • 6.2.2.2.2.Canada market size and forecast, by route of administration
      • 6.2.2.3.Mexico
      • 6.2.2.3.1.Mexico market size and forecast, by type
      • 6.2.2.3.2.Mexico market size and forecast, by route of administration
  • 6.3.Europe
    • 6.3.1.Key market trends and opportunities
    • 6.3.2.Market analysis by country
      • 6.3.2.1.UK
      • 6.3.2.1.1.UK market size and forecast, by type
      • 6.3.2.1.2.UK market size and forecast, by route of administration
      • 6.3.2.2.Germany
      • 6.3.2.2.1.Germany market size and forecast, by type
      • 6.3.2.2.2.Germany market size and forecast, by route of administration
      • 6.3.2.3.France
      • 6.3.2.3.1.France market size and forecast, by type
      • 6.3.2.3.2.France market size and forecast, by route of administration
      • 6.3.2.5.Italy
      • 6.3.2.5.1.Italy market size and forecast, by type
      • 6.3.2.5.2.Italy market size and forecast, by route of administration
      • 6.3.2.6.Spain
      • 6.3.2.6.1.Spain market size and forecast, by type
      • 6.3.2.6.2.Spain market size and forecast, by route of administration
      • 6.3.2.7.Rest of Europe
      • 6.3.2.7.1.Rest of Europe market size and forecast, by type
      • 6.3.2.7.2.Rest of Europe market size and forecast, by route of administration
  • 6.4.Asia-Pacific
    • 6.4.1.Key market trends and opportunities
    • 6.4.2.Market analysis by country
      • 6.4.2.1.Japan
      • 6.4.2.1.1.Japan market size and forecast, by type
      • 6.4.2.1.2.Japan market size and forecast, by route of administration
      • 6.4.2.2.China
      • 6.4.2.2.1.China market size and forecast, by type
      • 6.4.2.2.2.China market size and forecast, by route of administration
      • 6.4.2.3.Australia
      • 6.4.2.3.1.Australia market size and forecast, by type
      • 6.4.2.3.2.Australia market size and forecast, by route of administration
      • 6.4.2.4.India
      • 6.4.2.4.1.India market size and forecast, by type
      • 6.4.2.4.2.India market size and forecast, by route of administration
      • 6.4.2.5.Rest of Asia-Pacific
      • 6.4.2.5.1.Rest of Asia-Pacific market size and forecast, by type
      • 6.4.2.5.2.Rest of Asia-Pacific market size and forecast, by route of administration
  • 6.5.LAMEA
    • 6.5.1.Key market trends and opportunities
    • 6.5.2.Market analysis by country
      • 6.5.2.1.Brazil
      • 6.5.2.1.1.Brazil market size and forecast, by type
      • 6.5.2.1.2.Brazil market size and forecast, by route of administration
      • 6.5.2.2.South Africa6.5.2.2.1.South Africa market size and forecast, by type
      • 6.5.2.2.2.South Africa market size and forecast, by route of administration
      • 6.5.2.3.Saudi Arabia
      • 6.5.2.3.1.Saudi Arabia market size and forecast, by type
      • 6.5.2.3.2.Saudi Arabia market size and forecast, by route of administration
      • 6.5.2.4.Rest of LAMEA
      • 6.5.2.4.1.Rest of LAMEA market size and forecast, by type
      • 6.5.2.4.2.Rest of LAMEA market size and forecast, by route of administration

CHAPTER 7:COMPANY PROFILES

  • 7.1.ABBVIE INC.
    • 7.1.1.Company overview
    • 7.1.2.Company snapshot
    • 7.1.3.Operating business segments
    • 7.1.4.Product portfolio
    • 7.1.5.Business performance
  • 7.2.BAYER AG.
    • 7.2.1.Company overview
    • 7.2.2.Operating business segments
    • 7.2.3.Product portfolio
    • 7.2.4.Business performance
  • 7.3.BIOGEN
    • 7.3.1.Company overview
    • 7.3.2.Company snapshot
    • 7.3.3.Operating business segments
    • 7.3.4.Product portfolio
    • 7.3.5.Business performance
    • 7.3.6.Key strategic moves and developments
  • 7.4.BRISTOL-MYERS SQUIBB COMPANY
    • 7.4.1.Company overview
    • 7.4.2.Company snapshot
    • 7.4.3.Operating business segments
    • 7.4.4.Product portfolio
    • 7.4.5.Business performance
  • 7.5.F. HOFFMANN-LA ROCHE LTD.
    • 7.5.1.Company overview
    • 7.5.2.Company snapshot
    • 7.5.3.Operating business segments
    • 7.5.4.Business performance
    • 7.5.5.Key strategic moves and developments
  • 7.6.MERCK KGAA
    • 7.6.1.Company overview
    • 7.6.2.Company snapshot
    • 7.6.3.Operating business segments
    • 7.6.4.Product portfolio
    • 7.6.5.Business performance
  • 7.7.NOVARTIS AG.
    • 7.7.1.Company overview
    • 7.7.2.Company snapshot
    • 7.7.3.Operating business segments
    • 7.7.4.Product portfolio
    • 7.7.5.Business performance
    • 7.7.6.Key strategic moves and developments
  • 7.8.PFIZER INC.
    • 7.8.1.Company overview
    • 7.8.2.Company snapshot
    • 7.8.3.Operating business segments
    • 7.8.4.Product portfolio
    • 7.8.5.Business performance
  • 7.9.SANOFI
    • 7.9.1.Company overview
    • 7.9.2.Company snapshot
    • 7.9.3.Operating business segments
    • 7.9.4.Product portfolio
    • 7.9.5.Business performance
  • 7.10.TEVA PHARMACEUTICAL INDUSTRIES LTD.
    • 7.10.1.Company overview
    • 7.10.2.Company snapshot
    • 7.10.3.Operating business segments
    • 7.10.4.Product portfolio
    • 7.10.5.Business performance
    • 7.10.6.Key strategic moves and developments
株式会社グローバルインフォメーション
© Copyright 1996-2021, Global Information, Inc. All rights reserved.